Clay Siegall’s Remarkable Impact on Pharmacy

Clay Siegall, the CEO of Seattle Genetics, came up with the company in the year 1998. He is the President, Chief Executive Officer and the Chairman of the Board of the enterprise. He had previously worked at Bristol-Myers Squibb Pharmaceutical Research Institute, the National Cancer Institute, National Institute of Health. Siegall is one of the Board members of Ultragenyx Pharmaceutical, Biopharmaceuticals and Washington Roundtable.

His venture in this field began at the University of Maryland where he acquired a BSc. in Zoology. Later on, he pursued a Ph.D. in Genetics from George Washington University. Eventually, Clay Siegall has written over 70 publications in genetics.

His specialty was in being a scientist, specifically on cancer therapies. Seattle Genetics was made from deep scientific research, manufacturing of drugs and a desire to give assistance to the unwell. Up to now, Clay Siegall has led his company to a high cadre as a result of its success in coming up with antibody drug conjugates (ADC’s). In 2011, FDA gave the green light to the first ADC drugs, named ADCETRIS. Seattle Genetics formed a partnership with Takeda Pharmaceutical Company to promote ADCETRIS in the whole world. The partnership proved a success as the drug came to be endorsed in more than 65 states. The company is currently working on ADC’s to treat cancer.

The idea to form Seattle Genetics was motivated by the urge to help patients by improving the available resources. The success of the company is also because as an entrepreneur, he accepted that he didn’t know much and was willing to learn more. More so, he also saw the importance of incorporating other existing successful businesses in the field.

The excellent running of Seattle Genetics by Dr. Clay has enabled the company to collaborate in its activities, mainly the ADC technology, with other high-profile companies like GlaxoSmithKline and as a result made figures exceeding $350 million. The doctor has also secured funds, more than $1.2 billion to assist in his company’s operations.

Clay’s works have been recognized on many fronts, one of them being the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences and also the 2012 Pacific Northwest Ernst and Young Entrepreneur of the Year.